Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30006497 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL2508825 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL680110 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2108480 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7721751 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1569371 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL685097 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2055326 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21442028 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2055320 | 0.98 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | claimed |
| CN-120166994-A | Antiviral compounds | 豪夫迈·罗氏有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-114605310-B | Synthesis method of aza five-membered ring and three-membered ring carboxylic ester derivative and salt thereof | 都创(上海)医药科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024089159-A1 | MAIN PROTEASE INHIBITORS | UBIQ HOLDING B.V. (NL) | 2024-05-02 | — | — | WO | disclosed |
| CN-117447382-A | Preparation method of tetrahydropyrrolo cyclopropane | 武汉瑞晟药业有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115286559-B | Preparation method of key intermediate of anti-new crown drug Pa Luo Weide | 上海再启生物技术有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023200364-A1 | METHODS FOR PRODUCING (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПРОМОМЕД РУС" | 2023-10-19 | — | — | WO | disclosed |
| CN-116854768-A | Preparation method of Nemactetvir and intermediate thereof | 浙江九洲药业股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115108965-B | Preparation method of key intermediate of anti-new crown drug Pa Luo Weide | 上海再启生物技术有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-114133350-B | Preparation method of anti-neocrown drug Paxlovid intermediate | 浙江乐普药业股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023083926-A1 | SYNTHESIS OF (1R,2S,5S)-N-((S)-1-CYANO-2-((S)-2-OXOPYRROLIDIN-3-YL)ETHYL)-3-((S)-3,3-DIMETHYL-2- (2,2,2-TRIFLUOROACETAMIDO)BUTANOYL)-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE | KRKA, D.D., NOVO MESTO (SI) | 2023-05-19 | — | — | WO | disclosed |
| CN-115656402-A | Detection method of nemadevir related substances | 山东诚创蓝海医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115286559-A | Preparation method of anti-new crown drug Parovirid key intermediate | 上海再启生物技术有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114605310-A | Synthesis method of aza five-membered ring and three-membered ring carboxylate derivative and salt thereof | 都创(上海)医药科技股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114133350-A | Preparation method of anti-neocorolla drug Paxlovid intermediate | 浙江乐普药业股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2014648-A1 | PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | C9, NPPA, ADH1C | CHRNB4 3896/4885CHRNA3 4237/4885CHRNA7 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.